Ipamorelin vs Vesugen
Well Studied vs Moderate Research
synergistic Mechanism-based · 47% Ipamorelin and Vesugen work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
Ipamorelin Vesugen
Weight 711.85 Da 390 Da
Half-life ~2 hours Not established
Chain 5 amino acids 3 amino acids
Type Growth hormone secretagogue Tripeptide bioregulator
Key Benefits
Ipamorelin
01 Optimal GH stimulation with superior bioavailability
02 Body composition improvements (lean mass, fat loss)
03 Enhanced recovery and anti-aging effects
04 Minimal side effects compared to other GHRPs
05 No significant cortisol or prolactin elevation
06 Improved sleep quality
Vesugen
01 Protects vascular system from aging effects
02 Limits atherosclerosis development
03 Decreases endothelial cell dysfunction
04 Activates SIRT1 anti-aging pathway
05 Enhances stem cell proliferation
06 Reduces cellular senescence markers
07 Reverses SASP phenotype
08 Works synergistically with Cardiogen
Dosing Protocols
Ipamorelin
200-300 mcg per injection / 1-3 times daily depending on goals (1x for longevity, 2-3x for performance)
General Health & Longevity 200mcg 1x daily before bed
Body Composition 250-300mcg 2x daily (morning, pre-workout)
Athletic Performance 200-250mcg 2-3x daily
Sleep & Recovery 200mcg 1x daily 30min before bed
Anti-Aging Protocol 200-250mcg 1-2x daily
Vesugen
10-20 mg per day (oral capsules) or 10 mg (injectable) / Daily for 10-20 consecutive days (Khavinson bioregulator cycle)
Research protocol 10 mg Daily for 10 days
Side Effects
Ipamorelin
Mild hunger increase 20-30 minutes post-injection
Slight drowsiness when taken before bed
Water retention (mild)
Vesugen
Generally well-tolerated
Minimal side effects reported
Contraindications
Pregnancy or breastfeeding
Active cancer or history of cancer
Severe kidney or liver disease
Active cardiovascular emergencies (seek medical care)
Known hypersensitivity
Pregnancy or breastfeeding
Research Evidence
Ipamorelin Vesugen
Status Well Studied Moderate Research
References 5 studies 3 studies
Latest October 2024 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.